Skip to main content

Table 2 Baseline characteristics of 1227 patients who underwent resection for hepatocellular carcinoma with regular follow-up stratified by risk of recurrence and follow-up interval

From: Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study

Characteristics

Low-risk patients

High-risk patients

Long interval

Short interval

P

Long interval

Short interval

P

(n = 390)

(n = 475) (%)

(n = 149) (%)

(n = 213) (%)

Gender

  

0.926

  

0.001

 Male

344 (88.2)

418 (88)

 

123 (82.6)

199 (93.4)

 

 Female

46 (11.8)

57 (12.0)

 

26 (17.4)

14 (6.6)

 

Age (years)

52 (14)

50 (19)

0.072

51 (17)

49 (17)

0.292

Tumor number

  

0.273

  

0.891

 Solitary

359 (92.1)

427 (89.9)

 

92 (61.7)

130 (61)

 

 Multiple

31 (7.9)

48 (10.1)

 

57 (38.3)

83 (39)

 

Tumor size (cm)

  

0.458

  

0.674

 > 5

60 (15.4)

82 (17.3)

 

109 (73.2)

160 (75.1)

 

 ≤ 5

330 (84.6)

393 (82.7)

 

40 (26.8)

53 (24.9)

 

 Tumor size (cm)

3.5 (2.0)

3.5 (2.3)

0.288

8 (5.0)

8 (4.8)

0.916

Tumor location

  

0.054

  

0.287

 Central

96 (24.6)

145 (30.5)

 

16 (10.7)

16 (7.5)

 

 Subcapsular

294 (75.4)

330 (69.5)

 

133 (89.3)

197 (92.5)

 

Tumor differentiation

  

0.393

  

0.761

 Poor

45 (11.5)

64 (13.5)

 

20 (13.4)

31 (14.6)

 

 Moderate and well

345 (88.5)

411 (86.5)

 

129 (86.6)

182 (85.4)

 

Tumor MVI

  

0.627

  

0.126

 Yes

27 (6.9)

29 (6.1)

 

95 (63.8)

152 (71.4)

 

 No

363 (93.1)

446 (93.9)

 

54 (36.2)

61 (28.6)

 

BCLC stage

  

0.604

  

0.238

 0/A

380 (97.4)

460 (96.8)

 

110 (73.8)

145 (68.1)

 

 B

10 (2.6)

15 (3.2)

 

39 (26.2)

68 (31.9)

 

Etiology

  

0.901

  

0.694

 Non-hepatitis

37 (9.5)

47 (9.9)

 

18 (12.1)

22 (10.3)

 

 HBV

347 (89)

420 (88.4)

 

129 (86.6)

189 (88.7)

 

 HCV

6 (1.5)

8 (1.7)

 

2 (1.3)

2 (0.9)

 

WBC (109/L)

5.8 (1.9)

5.9 (2.3)

0.189

6.0 (2)

6.5 (2.8)

0.014

RBC (109/L)

4.73 (0.7)

4.8 (0.7)

0.123

4.75 (0.7)

4.81 (0.7)

0.460

 Hemoglobin (g/L)

147 (16.4)

146.7 (18)

0.922

144 (22)

145.9 (20.9)

0.392

PLT (109/L)

161.3 (79.3)

162 (72)

0.526

192 (88)

189 (77)

0.643

ALT (U/L)

36.9 (27.2)

36.1 (23.7)

0.857

37 (26.7)

39.8 (29.6)

0.196

AST (U/L)

31.2 (16.8)

31.5 (14.8)

0.882

39.4 (25.4)

40.7 (25.2)

0.774

ALB (g/L)

42.8 (4.6)

43.1 (4.5)

0.083

42.2 (4.7)

43 (4.4)

0.074

TBIL (μmol/L)

12.9 (5.9)

13.4 (6.5)

0.129

12.2 (6.2)

12.7 (5.8)

0.502

PT (s)

11.7 (1.3)

11.6 (1.2)

0.590

11.6 (1.2)

11.6 (1.1)

0.615

ALBI grade

  

0.720

  

0.432

 I

335 (85.9)

412 (86.7)

 

116 (77.9)

173 (81.2)

 

 II

55 (14.1)

63 (13.3)

 

33 (22.1)

40 (18.8)

 

AFP (ng/mL)

  

0.289

  

0.905

 > 200

111 (28.5)

151 (31.8)

 

66 (44.3)

93 (43.7)

 

 ≤ 200

279 (71.5)

324 (68.2)

 

83 (55.7)

120 (56.3)

 

Cirrhosis

  

0.957

  

0.296

 Yes

288 (73.8)

350 (73.7)

 

95 (63.8)

147 (69)

 

 No

102 (26.2)

125 (26.3)

 

54 (36.2)

66 (31)

 

Resection margin (cm)

1 (1.5)

1 (1.15)

0.526

1 (1.5)

1 (1.5)

0.894

Operative blood loss (ml)

  

0.691

  

0.173

 > 400

45 (11.5)

59 (12.4)

 

52 (34.9)

60 (28.2)

 

 ≤ 400

345 (88.5)

416 (87.6)

 

97 (65.1)

153 (71.8)

 
  1. Values are presented as the median (interquartile range) or n (%)
  2. MVI microvascular invasion, BCLC stage Barcelona clinic liver cancer stage, HBV hepatitis B virus, HCV hepatitis C virus, WBC white blood cell, RBC red blood cell, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, PT prothrombin time, ALBI albumin-bilirubin, AFP alpha-fetoprotein
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us